Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Huge canadian study tracks rare cancer mutations to improve treatment

NCT ID NCT04151342

Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting information from 5,500 Canadian cancer patients whose tumors have rare genetic changes. Researchers want to see how well current targeted drugs work for these uncommon mutations. Participants are observed over time, and their treatment outcomes, side effects, and quality of life are tracked. The goal is to learn more about these rare cancers and help guide future treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better match rare genetic changes in tumors with the right targeted drugs, improving treatment decisions for future patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may take years and might not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cancer patients living and deceased who have/had a histologically confirmed rare molecular alteration in their tumours, such as but not limited to ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years at cancer diagnosis * Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations * Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \[PCR\] based next generation sequencing \[NGS\], immunohistochemistry \[IHC\], fluorescence in situ hybridization \[FISH\], liquid biopsy) * Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment Exclusion Criteria: * Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Congenital Abnormalities neoplasm Neoplasms, Second Primary therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Cancer, therapy-related Gene fusion Genetic alteration Malignancies multiple Malignant solid tumor Molecular sequence variation Ras (KRAS or NRAS) gene mutation Receptor tyrosine kinase gene mutation RTK family gene mutation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    NOT_YET_RECRUITING

    Regina, Saskatchewan, Canada

  • BC Cancer

    RECRUITING

    Vancouver, British Columbia, Canada

  • CancerCare Manitoba/University of Manitoba

    RECRUITING

    Winnipeg, Manitoba, Canada

  • Centre hospitalier de l'Université de Montréal (CHUM)

    RECRUITING

    Montreal, Quebec, Canada

  • Centre hospitalier de l'université de Québec - Université Laval

    NOT_YET_RECRUITING

    Québec, Quebec, Canada

  • Centre hospitalier universitaire de Sherbrooke (CHUS)

    RECRUITING

    Sherbrooke, Quebec, Canada

  • Cross Cancer Institute, University of Alberta - Alberta Health Services

    NOT_YET_RECRUITING

    Edmonton, Alberta, Canada

  • Dr. Everett Chalmers Regional Hospital

    RECRUITING

    Fredericton, New Brunswick, Canada

  • Dr. H. Bliss Murphy Cancer Centre

    NOT_YET_RECRUITING

    St. John's, Newfoundland and Labrador, Canada

  • Hamilton Health Sciences - Juravinski Cancer Centre

    RECRUITING

    Hamilton, Ontario, Canada

  • Health Sciences North

    RECRUITING

    Greater Sudbury, Ontario, Canada

  • Hôpital du Sacré-Coeur-de-Montréal (HSCM)

    RECRUITING

    Montreal, Quebec, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie de Québec

    NOT_YET_RECRUITING

    Québec, Quebec, Canada

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, Canada

  • Kingston Health Sciences Centre (KHSC)

    RECRUITING

    Kingston, Ontario, Canada

  • Lawson Health Research Institute - London Health Sciences Centre

    RECRUITING

    London, Ontario, Canada

  • McGill University Health Centre

    NOT_YET_RECRUITING

    Montreal, Quebec, Canada

  • Mount Sinai Hospital

    RECRUITING

    Toronto, Ontario, Canada

  • Ottawa Hospital Cancer Centre

    RECRUITING

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre (PMCC) - University Health Network (UHN)

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Queen Elizabeth II (QEII) Health Sciences Centre

    RECRUITING

    Halifax, Nova Scotia, Canada

  • Saskatoon Cancer Centre

    NOT_YET_RECRUITING

    Saskatoon, Saskatchewan, Canada

  • St. Mary's Hospital Center

    NOT_YET_RECRUITING

    Montreal, Quebec, Canada

  • Sunnybrook Research Institute - Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, Canada

  • Thunder Bay Regional Health Sciences Centre

    NOT_YET_RECRUITING

    Thunder Bay, Ontario, Canada

  • Tom Baker Cancer Centre - University of Calgary - Alberta Health Services

    RECRUITING

    Calgary, Alberta, Canada

  • William Osler Health System - Brampton Civic Hospital

    RECRUITING

    Brampton, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.